Restoring gut balance with natural and probiotic extracts for people with acute coronary syndromes
Official title: Metabolomic and Cellular Inflammaging Investigation Study of Patients With Acute Coronary Syndrome (ACS)
Run by Casa di Cura Dott. Pederzoli · NCT07429227 · Data updated 2026-11-12
This test checks whether high-bioavailability essential oil formulations and probiotic approaches can restore healthy gut bacteria in adults aged 30–70 hospitalized with acute coronary syndromes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 70 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Casa di Cura Dott. Pederzoli Academic / other |
| Drugs / interventions | Evolocumab, Alirocumab |
| Locations | 1 site (Peschiera del Garda, Verona) |
| Status | Recruiting |
| Started | March 2026 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | February 24, 2026 |
| Trial ID | NCT07429227 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 30–70 with a confirmed diagnosis of acute coronary syndrome (unstable angina or AMI) who can give informed consent and are not taking excluded lipid-lowering medications are eligible.
✕Probably not a fit
People with HIV, cancer, type 1 or type 2 diabetes, those taking excluded lipid-lowering drugs or nutraceuticals, and pregnant women are unlikely to be eligible or to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Patients admitted with unstable angina or acute myocardial infarction provide baseline urine and blood samples at admission and additional timed urine samples over the first 24 hours to capture intestinal permeability and dysbiosis markers. Participants then receive a two-month course of specified essential oil formulations and non-pharmacological therapy and return for a first-morning urine collection for metabolomics and dysbiosis testing. The study compares the initial 'snapshot' of gut-related biomarkers to the results after two months and records any adverse events or treatment discontinuations. Individuals using certain lipid-lowering drugs or with major comorbidities are excluded to reduce confounding.
Why it matters
Potential benefit: If successful, this could offer a non-drug approach to help restore gut balance after an acute coronary event, potentially lowering inflammation-related complications.
How similar studies have gone: Some prior small studies have linked microbiome changes to cardiovascular risk, but using targeted high-bioavailability essential oil formulations in ACS patients is largely novel and not well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Signing of informed consent * 2\. Diagnosis of Acute Coronary Syndrome (ACS) * 3\. Age 30-70 Exclusion Criteria: 1. Use in the three months preceding the signing of the informed consent of: i) Lipid-lowering drugs containing statins, ezetimibe, fibrates ii) Lipid-lowering nutraceuticals containing monacolin K iii) Monoclonal antibodies that inhibit PCSK9 (proprotein convertase subtilisin/kexin type 9) such as Evolocumab and Alirocumab 2. Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.
Where it's running
-
Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
Peschiera del Garda, Verona, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Drug-coated balloons vs drug-eluting stents for immediate slow-flow/no-reflow in STEMI with high thrombus
This study tests whether using a drug-coated balloon instead of a drug-eluting stent during PCI helps reduce immediate slow-flow or no-reflow in STEMI patients with high thrombus burden.
-
New prodrug CG-0255 Besylate vs Plavix in healthy adults
This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.
-
Biomarker patterns in ACS patients with pneumonia and COPD after flu vaccination
This study tests whether certain blood biomarkers change in people with acute coronary syndrome who also have pneumonia and COPD, and whether flu vaccination affects those biomarker levels.
-
Prehospital High-Sensitivity Troponin I to rule out heart attack for EMS patients
EMS patients with chest pain or possible heart symptoms are being studied to see if a portable hs-TnI test in the ambulance can help identify those at low risk for a heart attack.
-
IVUS-guided versus angiography-guided stent placement for acute coronary syndrome
This test will see if using intravascular ultrasound (IVUS) to guide stent placement helps adults with acute coronary syndrome more than standard angiography-guided PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.